RPRX
Royalty Pharma plc
NASDAQ · USHealthcareBiotechnology
$57.30-1.52%
Price as of Jul 20, 2026
RPRX valuation
Royalty Pharma plc valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- 10.52x
- P/E 2026E
- 11.91x
- P/E 2027E
- 11.05x
- P/E 2028E
- 9.68x
- P/S forward
- 7.12x
Trailing multiples
- P/E TTM
- 23.25x
- PEG TTM
- 0.19x
- Price / book
- 3.69x
- Price / sales
- 10.41x
- Price / cash flow
- 9.57x
Enterprise value
- Enterprise value
- $36.8B
- EV / sales
- 15.08x
- EV / EBITDA
- 21.66x
- EV / EBIT
- 22.19x
- Market cap
- $25.4B
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.